696 filings
Page 18 of 35
6-K
07p4pmbz5lt7u1
20 Sep 18
RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference
7:00am
6-K
sfbveiym
12 Sep 18
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
12:00am
6-K
6vn3g3gc 5urh
6 Sep 18
RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma
12:00am
6-K
hn0p oo586o83dgsaduj
4 Sep 18
RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA® for H. pylori Infection
12:00am
6-K
wfiyn m07n
30 Aug 18
Current report (foreign)
12:00am
6-K
izawnftr8gyothx2d9xs
24 Aug 18
Current report (foreign)
12:00am
6-K
re325ayqd3b7a
20 Aug 18
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation
12:00am
6-K
vmowo6qv7w35
14 Aug 18
RedHill Biopharma Announces Closing of $25 Million Underwritten Offering
10:17am
6-K
182 el0qssfuiay
13 Aug 18
Current report (foreign)
12:30pm
6-K
qdjdoocv
13 Aug 18
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections
7:00am
6-K
kfq8hg8k9rwsxxxoro
9 Aug 18
RedHill Biopharma Announces Pricing of $25 Million Underwritten Offering
9:10am
6-K
6hcatdz vfct54lvzu
1 Aug 18
RedHill Biopharma Elaborates on Its Announced Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
8:18am
6-K
535pj6xwc qq
30 Jul 18
RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
12:00am
6-K
3t0osoh0
25 Jul 18
Current report (foreign)
8:00am
6-K
7dejk2sx1c10rth 1eh
24 Jul 18
RedHill Biopharma Enrolls 400th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
8:23am
6-K
lph3u0ap1gtjozruce
23 Jul 18
RedHill Biopharma Announces Uplisting to Nasdaq Global Market
7:15am
6-K
n3g3ug8ja487h5fcup
2 Jul 18
Current report (foreign)
7:00am
6-K
ipct x3ce9r
28 Jun 18
Current report (foreign)
9:00am
6-K
34lwosnb9 jk
30 May 18
RedHill Biopharma to Present Positive Phase II Results of BEKINDA® for IBS-D at Digestive Disease Week 2018
8:01am
6-K
94xtz1p
29 May 18
RedHill Biopharma Announces New U.S. Patent for its Experimental Ebola Therapy
8:01am